Rusan Pharma, a global leader in healthcare and addiction treatment solutions, has recently achieved a groundbreaking milestone with the launch of its state-of-the-art Active Pharmaceutical Ingredients (API) facility in Pithampur, Special Economic Zone (SEZ), Madhya Pradesh. This strategic move underscores Rusan Pharma’s commitment to combating the increasing challenges in pain management and addiction, while significantly contributing to the growth of the Indian pharmaceutical industry.

Investment and Technological Advancements

The new facility represents a substantial investment of up to INR 300 crores over two phases, highlighting Rusan Pharma’s dedication to the pharmaceutical sector. Designed to meet stringent international regulatory guidelines, the facility boasts a production capacity of 400 metric tonnes of APIs annually, marking a pivotal step in Rusan Pharma’s expansion and diversification plans.

Comments from Rusan Pharma Leadership

Dr. Navin Saxena, Founder and Chairman of Rusan Pharma, emphasized the facility’s role in enhancing API capacity and securing the supply of critical APIs for addiction treatment and pain management products. Dr. Kunal Saxena, Managing Director, highlighted the facility’s alignment with the ‘Make in India’ initiative, particularly in controlled substances, and its contribution to reducing import dependency.

Strategic Location and Environmental Commitment

Strategically located in Pithampur SEZ, the facility benefits from state government support and subsidies. Its position in a pharmaceutical zone minimizes pollution risks from other industries. The facility sets itself apart with world-class automation, in-house design optimization, and a commitment to environmental controls, resulting in higher yields, reduced production costs, and exceptional product quality.

Architectural Marvel and Employment Opportunities

The facility is not only an architectural marvel designed to minimize disruption to natural terrain but also a hub for job creation. It has employed over 3000 contract workers during construction and will generate more than 300 direct and 500+ indirect employment opportunities when fully operational.

Rusan Pharma’s Diverse Portfolio and Global Impact

Rusan Pharma has continuously diversified its portfolio, investing heavily in R&D to develop advanced products. It was the first company in India to introduce Buprenorphine Sublingual and Buprenorphine Naloxone Sublingual Tablets for drug abuse treatment. The company’s GMP-approved facilities cater to a significant portion of the global demand, with accreditations from multiple international regulatory bodies.

Rusan Pharma’s new API facility in Pithampur SEZ is a testament to its innovative approach and unwavering commitment to enhancing global healthcare, particularly in the realms of pain management and addiction treatment.

  Dr. Navin Saxena, India, Madhya Pradesh, Pithampur, Rusan Pharma